Osaic Holdings
HRTX icon

Osaic Holdings’s Heron Therapeutics HRTX Stock Holding History

Osaic Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15
Closed -$2K – 7051
2021
Q1 		$2K Buy
+15
New +$267 ﹤0.01% 6482

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Osaic Holdings's HRTX Position: Q1 2026 in Review

Osaic Holdings reduced its Heron Therapeutics (HRTX) stake by 22% in Q1 2026, selling an estimated $1.28K and leaving 3,861 shares worth $3.09K. The position accounts for ﹤0.01% of the portfolio, ranked #6890.

Osaic Holdings first reported a position in HRTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $652K in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Osaic Holdings held 3,861 shares of Heron Therapeutics worth $3.09K as of Q1 2026.
  • Osaic Holdings sold 1,107 Heron Therapeutics shares in Q1 2026, an estimated $1.28K.
  • Heron Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #6890 holding.
  • Osaic Holdings first reported a position in Heron Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Osaic Holdings's Heron Therapeutics position peaked at $652K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.